个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共14条记录   Discontinued drugs in 2008: cardiovascular drugs [作者：Zhang, XS; Xiang, BR,期刊：Expert opinion on investigational drugs, 页码：875-885 , 文章类型： Editorial Material，,卷期：2009年18-7] This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 16 cardiovascular drugs discontinued in 2008. inform... Oral laquinimod therapy in relapsing multiple sclerosis [作者：Preiningerova, J,期刊：Expert opinion on investigational drugs, 页码：985-989 , 文章类型： Editorial Material，,卷期：2009年18-7] Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS. Early treatment reduces the number of relapses, limits progression of disability, and improves quality of life; however, existing therapies ... The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma [作者：Yamane, BH; Hank, JA; Albertini, MR; Sondel, PM,期刊：Expert opinion on investigational drugs, 页码：991-1000 , 文章类型： Editorial Material，,卷期：2009年18-7] Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL-2 (EMD-273063) was devel... Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer [作者：Madan, RA; Arlen, PM; Mohebtash, M; Hodge, JW; Gulley, JL,期刊：Expert opinion on investigational drugs, 页码：1001-1011 , 文章类型： Editorial Material，,卷期：2009年18-7] Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector as a primary vaccination, followed by multiple booster vaccinations employing a recombinant fowlpox vector. Both vectors contain t... Sustained-release fampridine for multiple sclerosis [作者：Bever, CT; Judge, SIV,期刊：Expert opinion on investigational drugs, 页码：1013-1024 , 文章类型： Editorial Material，,卷期：2009年18-7] Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system of unknown cause in which neurological impairment and disability result from demyelination and axonal loss. Ph... Cixutumumab [作者：McKian, KP; Haluska, P,期刊：Expert opinion on investigational drugs, 页码：1025-1033 , 文章类型： Editorial Material，,卷期：2009年18-7] The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigation... Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor [作者：Garvey, L; Winston, A,期刊：Expert opinion on investigational drugs, 页码：1035-1041 , 文章类型： Editorial Material，,卷期：2009年18-7] Combination antiretroviral therapy has transformed the prognosis and life expectancy of HIV-1 infected individuals in resource-rich settings. British guidelines currently recommend the non-nucleoside reverse transcriptas... Tesofensine - a novel potent weight loss medicine [作者：Doggrell, SA,期刊：Expert opinion on investigational drugs, 页码：1043-1046 , 文章类型： Editorial Material，,卷期：2009年18-7] Background: The incidence of obesity is increasing; this is of major concern, as obesity is associated with cardiovascular disease, stroke, type 2 diabetes, respiratory tract disease, and cancer. Objectives/methods: This... Growth hormone: does it have a therapeutic role in fracture healing? [作者：Tran, GT; Pagkalos, J; Tsiridis, E; Narvani, AA; Heliotis, M; Mantalaris, A; Tsiridis, E,期刊：Expert opinion on investigational drugs, 页码：887-911 , 文章类型： Review，,卷期：2009年18-7] Background: The role of growth hormone (GH) in augmenting fracture healing has been postulated for over half a century. GH has been shown to play a role in bone metabolism and this can be mediated directly or indirectly ... Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options [作者：Davies, JM; O'Neil, B,期刊：Expert opinion on investigational drugs, 页码：913-919 , 文章类型： Review，,卷期：2009年18-7] Background: certain malignancies, associated with a poor prognosis and limited treatment options. Generally, PC has been treated similarly to metastatic cancers of the primary tumor, but associated with worse outcomes wh... Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies [作者：Falagas, ME; Roussos, N; Gkegkes, LD; Rafailidis, PI; Karageorgopoulos, DE,期刊：Expert opinion on investigational drugs, 页码：921-944 , 文章类型： Review，,卷期：2009年18-7] Background: The advancing antimicrobial drug resistance in Gram-positive cocci complicates the selection of appropriate therapy. The re-evaluation of older antibiotics may prove useful in expanding relevant therapeutic o... Novel investigational drugs for gastric cancer [作者：Vecchione, L; Orditura, M; Ciardiello, F; De Vita, F,期刊：Expert opinion on investigational drugs, 页码：945-955 , 文章类型： Review，,卷期：2009年18-7] Background: Gastric cancer still represents a leading cause of death worldwide. Several cytotoxic agents have demonstrated activity and combination regimens improve progression-free survival, overall survival and quality... Clinical development of novel proteasome inhibitors for cancer treatment [作者：Yang, HJ; Zonder, JA; Dou, QP,期刊：Expert opinion on investigational drugs, 页码：957-971 , 文章类型： Review，,卷期：2009年18-7] Background: Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy. Objective: This review summarizes recent results from cancer clinical trials using specific prote... Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives [作者：Samuel, DP; Wen, PY; Kieran, MW,期刊：Expert opinion on investigational drugs, 页码：973-983 , 文章类型： Review，,卷期：2009年18-7] Significant advances in the diagnosis and treatment of brain tumors have been made through better imaging, surgical techniques and advances in radiation therapy. However, the cure rate for most adult and pediatric brain ...